Glaukos Corp., of San Clemente, Calif., scored an earlier-than-expected approval for its Istent Inject trabecular micro-bypass system, which is indicated for the reduction of intraocular pressure (IOP) in adult patients with mild-to-moderate primary open-angle glaucoma (POAG) who are undergoing cataract surgery.